Home » Newsletters » BioWorld

BioWorld

Sep. 2, 1993

View Archived Issues

PERSEPTIVE TO ACQUIRE MASS SPECTROMETRY COMPANY

CLOT-BUSTER STUDY RESULTS PUBLISHED

IMMUNOGEN TESTS ONCOLYSIN S

IVAX COMPLETES JOHNSON PRODUCTS MERGER

STOCK PURCHASE BRINGS VIRATEK $14M

VESTAR ENTERS TAXOL MARKET

FDA POSTPONES REVIEW OF RESPIVIR

FDA APPROVES HYGEIA PHARMACEUTICALS TRIALS

CYANOTECH GETS FUNDING FOR PRODUCTION FACILITY

SOUTH KOREA OKS BTG'S BIOLON By Brenda Sandburg

APS COMPLETES PHASE III TRIALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...